BIX 01294

目录号：S8006 Purity: 99.08%

BIX01294 是一种G9a histone methyltransferase抑制剂，无细胞试验中IC50为2.7 μM，降低大部分组蛋白H3K9me2，也微弱抑制GLP（主要是H3K9me3），对其他组蛋白甲基转移酶没有显著的抑制活性。BIX01294 可诱导自噬。BIX01294 还可通过癌蛋白 NSD1、NSD2 和 NSD3 来抑制H3K36甲基化。

BIX 01294 Chemical Structure

CAS: 1392399-03-9

规格	价格	库存
10mM (1mL in DMSO)	1566.17	现货
10mg	1222.94	现货
50mg	3415.23	现货
1g	17772.3	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.08%

99.08

BIX 01294相关产品

相关靶点	Menin-MLL interaction WDR5-MLL interaction	点击展开
相关产品	GSK126 DZNeP (3-deazaneplanocin A) HCl GSK343 Pinometostat (EPZ5676) EPZ004777 EPZ015666 (GSK3235025) UNC1999 Chaetocin EPZ005687 Pemrametostat (GSK3326595) SGC 0946 MM-102 UNC0638 EPZ011989 UNC0642 OICR-9429 UNC0379 GSK591 Lirametostat (CPI-1205) MI-2 (Menin-MLL Inhibitor) CPI-169 MI-503 MS023 A-196 GSK503 AMI-1 PFI-2 HCl SGC707 A-366 MI-3 (Menin-MLL Inhibitor) BRD4770 LLY-507 Onametostat (JNJ-64619178) WDR5-0103 EI1 UNC3866 EPZ020411 2HCl MI-463 HLCL-61 HCL MAK683 MI-136 MS049 SAH (S-Adenosyl-L-homocysteine) PF-06726304 CPI-360 JQ-EZ-05 (JQEZ5) SGC2085	点击展开
相关化合物库	激酶抑制剂库 FDA药物库天然产物库已知活性药物库-I 高选择性抑制剂库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
K562	Function assay	0.5 to 2 uM	72 hrs	Inhibition of histone methyltransferase G9a in human K562 cells assessed as reduction in histone H3K9me2 levels at 0.5 to 2 uM after 72 hrs by Western blot analysis	27393948
HeLa	Function assay		4.5 hrs	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay, IC50 = 0.966 μM.	29624387
BL21 (DE3)-Gold	Function assay		20 mins	Inhibition of N-terminal hexahistidine-tagged human G9a (913 to 1193 residues) expressed in Escherichia coli BL21 (DE3)-Gold cells using histone H3 (1 to 15 residues) as substrate preincubated for 20 mins followed by substrate addition by mass spectrometr, IC50 = 1.9 μM.	27720557
HL60	Antiproliferative assay		48 hrs	Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay, IC50 = 2.2 μM.	27393948
A549	Antiproliferative assay		48 hrs	Antiproliferative activity against human A549 cells after 48 hrs by CCK8 assay, IC50 = 2.8 μM.	27393948
HepG2	Antiproliferative assay		48 hrs	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay, IC50 = 3.7 μM.	27393948
K562	Antiproliferative assay		48 hrs	Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay, IC50 = 3.9 μM.	27393948
MDA-MB-231	Function assay		2 days	Inhibition of G9a in human MDA-MB-231 cells assessed as reduction in H3K9me2 level after 2 days by immunofluorescence in-cell western analysis, IC50 = 4.563 μM.	29541353
HeLa cells	Function assay			Inhibition of ERK5 phosphorylation in sorbitol-stimulated human HeLa cells, IC50=0.059 μM	23656407
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
wild type fibroblast cells	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	29435139
点击查看更多细胞系数据

生物活性

产品描述

靶点

G9a ^[1]
(Cell-free assay)

2.7 μM

体外研究(In Vitro)
体外研究活性	BIX01294是选择性的G9a组蛋白甲基转移酶抑制剂，在实验浓度范围内不影响SUV39H1(H320R)和PRMT1。BIX-01294特异性抑制G9a (H3K9me2)，并在较小程度上抑制密切相关的GLP酶（主要是H3K9me3），作用于G9a 和GLP，IC50分别为1.7 μM 和 38 μM。BIX-01294抑制G9a，与SAM按非竞争性的方式。BIX-01294 (4.1μM) 作用于野生型ES细胞，小鼠胚胎成纤维细胞和HeLa细胞，而非缺乏G9a的干细胞，降低H3K9me2水平。BIX-01294是抑制有价值的染色体H3K9me2瞬态调制的抑制剂。BIX-01294在一些G9a靶向基因上，包括Bim1 和Serac1，降低H3K9me2。^[1] BIX01294可使HIV-1病毒从潜伏感染的细胞，如ACH-2和 OM10.1中重新表达。^[2]
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	Atg7 / Atg5 / Atg5-Atg12 / Atg3 / Atg12 / LC3B G9a / H3K9me2 Cyclin D1 / CDK2 / CDK4 / CDK 6 / Cyclin E		25198515
	Immunofluorescence	Ran / H3K9me3		30565836
	Growth inhibition assay	Cell viability		26013382

参考文献
[1] Kubicek S, et al. Mol Cell, 2007, 25(3), 473-481. [2] Imai K, et al. J Biol Chem, 2010, 285(22), 16538-16545. [3] Mabe NW, et al. Cell Rep. 2020 Nov 3;33(5):108341.

参考文献

化学信息&溶解度

分子量	600.02	分子式	C₂₈H₃₈N₆O₂.3HCl
CAS号	1392399-03-9	SDF	Download BIX 01294 SDF
Smiles	CN1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)NC4CCN(CC4)CC5=CC=CC=C5)OC)OC.Cl.Cl.Cl
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 100 mg/mL ( (166.66 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 100 mg/mL (166.66 mM)

Ethanol : 100 mg/mL (166.66 mM)

DMSO : 100 mg/mL ( (166.66 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 100 mg/mL (166.66 mM)

Ethanol : 25 mg/mL (41.66 mM)

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):